IE 11 is not supported. For an optimal experience visit our site on another browser.

Advanced Medical Isotope Corporation Engages The Investor Relations Group

KENNEWICK, Wash., Feb. 10, 2011 (GLOBE NEWSWIRE) -- Advanced Medical Isotope Corporation (OTCBB:ADMD), a company engaged in the production and distribution of medical isotopes, has hired The Investor Relations Group ("IRG"), a fourteen-year-old, award-winning, corporate communications firm based in New York City, to serve as its investor relations and public relations agency.
/ Source: GlobeNewswire

KENNEWICK, Wash., Feb. 10, 2011 (GLOBE NEWSWIRE) -- Advanced Medical Isotope Corporation (OTCBB:ADMD), a company engaged in the production and distribution of medical isotopes, has hired The Investor Relations Group ("IRG"), a fourteen-year-old, award-winning, corporate communications firm based in New York City, to serve as its investor relations and public relations agency.

IRG's investor relations team will target specific portfolio managers and equity analysts in the global investment community to increase awareness of Advanced Medical Isotope Corporation's medical isotope products and services. Concurrent with that effort, the public relations team will initiate an outreach campaign targeting editors, writers, and segment producers of local and national trade and consumer online, print, radio, and broadcast media outlets worldwide.

"Advanced Medical Isotopes has outlined a bold set of initiatives for 2011, and we are confident that IRG will serve as an excellent liaison to the investment community and the media at large," commented James C. Katzaroff, Chairman and Chief Executive Officer. "Given the severity of the current shortage of available medical isotopes in the U.S., we believe that domestic production is an urgent matter, and are working with partners to produce isotopes for diagnostic and therapeutic uses. We look forward to working with IRG as we achieve our objectives, and will update the investment community as we move ahead."

IRG's corporate communications program includes new media and multimedia initiatives that involve the creation of broadcast-ready corporate videos, podcasts, and the creation of social networking, video service, and micro-blogging accounts. The Investor Relations Group was recently honored with a "Stevie Award" for Investor Relations Program of the Year and named a finalist in the Best Media Website category from the 2009 American Business Awards.

About Advanced Medical Isotope Corporation

Advanced Medical Isotope Corporation (OTCBB:ADMD) is a company engaged in the production and distribution of medical isotopes for advanced diagnostic and non-surgical therapeutic application. AMIC's goal is to empower physicians, medical researchers, and ultimately patients by providing them with essential medical isotopes that, until recently, have not been feasible or economical, in an effort to detect and cure human disease. For more information, please visit our website, .

The Advanced Medical Isotope Corporation logo is available at .

About The Investor Relations Group, Inc.

The Investor Relations Group, Inc. (IRG) offers a full-service corporate communications program designed to suit the many unique needs of Alternative Public Offering (APO) companies. The program utilizes a proprietary, targeted approach to reach institutional investors, analysts, and the media-at-large. For further information, please visit the company's website at .

Safe Harbor Statement

The information posted in this release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by the use of the words "may," "will," "should," "plans," "expects," "anticipates," "continue," "estimates," "projects," "intends," and similar expressions. Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technical advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, government agency rules and changes, and various other factors beyond the Company's control.

CONTACT: Advanced Medical Isotope Corporation James C. Katzaroff (509) 736-4000 The Investor Relations Group 11 Stone St. 3rd Floor New York, NY 212-825-3210 IR: Adam Holdsworth/James Carbonara or PR: Laura Colontrelle/Janet Vasquez